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Summary
Background.  —  Radiofrequency  ablation  (RFA)  of  paroxysmal  atrial  ﬁbrillation  (PAF)  has  focused
on pulmonary  vein  isolation  (PVI).  However,  despite  initial  positive  results,  signiﬁcant  recurr-
ences have  occurred,  partly  because  of  pulmonary  vein  (PV)  reconnection  or  non-PV  ectopic
foci, including  the  superior  vena  cava  (SVC).
Objectives.  —  This  prospective,  randomized  study  sought  to  investigate  the  efﬁcacy  of  addi-
tional SVCI  combined  with  PVI  in  symptomatic  PAF  patients  referred  for  ablation.
®Randomized  study Methods.  —  From  November  2011  to  May  2013,  RFA  was  performed  remotely  using  a  CARTO
3  System  in  patients  randomized  to  undergo  PVI  for  symptomatic  drug-refractory  PAF,  with
(PVI +  SVCI  group)  or  without  (PVI  alone  group)  SVCI.  PVI  and  SVCI  were  conﬁrmed  by  spiral
catheter recording  during  ablation.  Procedural  data,  complications  and  freedom  from  atrial
tachycardia  (AT)  and  atrial  ﬁbrillation  (AF)  were  assessed.
Abbreviations: 3D, three-dimensional; AF, atrial ﬁbrillation; AT, atrial tachycardia; LA, left atrium/atrial; PAF, paroxysmal atrial ﬁbrilla-
tion; PV, pulmonary vein; PVI, pulmonary vein isolation; RA, right atrium; RFA, radiofrequency ablation; RMNS, remote magnetic navigation
system; SVC, superior vena cava; SVCI, superior vena cava isolation; VKA, vitamin K antagonists.
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Results.  —  Over  an  18-month  period,  100  consecutive  patients  (56  ±  9  years;  17  women)  with
symptomatic  PAF  were  included  in  the  study  (PVI  +  SVCI,  n  =  51;  PVI,  n  =  49);  the  CHA2DS2-VASc
score was  0.9  ±  1.  Median  duration  of  procedure  (±  interquartile),  2.5  ±  1  hours;  total  X-ray
exposure,  13.3  ±  8  minutes;  transseptal  puncture  and  catheter  positioning,  8  ±  5  minutes;  left
atrium electroanatomical  reconstruction,  3  ±  2  minutes;  and  catheter  ablation,  3.7  ±  3  minutes.
After a  median  follow-up  of  15  ±  8  months,  and  having  undergone  a  single  procedure,  84%  of
patients  were  symptom  free,  while  86%  remained  asymptomatic  after  undergoing  two  proce-
dures. The  cumulative  risks  of  atrial  arrhythmias  (AT  or  AF)  were  interpreted  using  Kaplan-Meier
curves and  compared  using  the  log-rank  test.  Long-term  follow-up  revealed  no  signiﬁcant  dif-
ference between  groups,  with  atrial  arrhythmias  occurring  in  six  (12%)  patients  in  the  PVI  +  SVCI
group and  nine  (18%)  patients  in  the  PVI  alone  group  (P  =  0.6).  One  transient  phrenic  nerve  palsy
and one  phrenic  nerve  injury  with  partial  recovery  occurred  in  the  PVI  +  SVCI  group.
Conclusions.  —  SVCI  combined  with  PVI  did  not  reduce  the  risk  of  subsequent  AF  recurrence,
and was  responsible  for  two  phrenic  nerve  injuries.  Accordingly,  the  beneﬁt-to-risk  ratio  argues
against systematic  SVCI.
©  2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  L’ablation  par  radiofréquence  (RFA)  de  la  ﬁbrillation  atriale  paroxystique  (FAP)
repose sur  l’isolement  des  veines  pulmonaires  (VPs).  Malgré  les  bons  résultats  de  la  technique,
il existe  un  taux  d’échec  et  de  récidives  non  négligeables  qui  peuvent  être  dus  soit  à  des
reconnections  de  VPs,  soit  à  d’autre  sources  dont  l’origine  peut-être  la  veine  cave  supérieure
(VCS). Les  données  de  la  littérature  sont  controversées  sur  l’intérêt  de  l’isolement  systématique
de la  VCS  en  combinaison  avec  l’isolement  des  VPs  dans  le  traitement  de  la  FAP.
Objectifs.  —  Cette  étude  randomisée  a  cherché  à  évaluer  l’efﬁcacité  de  l’isolement  systéma-
tique de  la  VCS  en  complément  de  l’isolement  des  VPs  chez  les  patients  avec  FA  paroxystique
symptomatique  par  la  technique  de  robot  magnétique.
Méthodes.  —  De  novembre  2011  à  mai  2013,  les  patients  devant  bénéﬁcier  d’un  traitement  par
RFA pour  FAP  étaient  randomisés  soit  dans  un  groupe  avec  isolement  des  VPs  couplé  à  un  isole-
ment de  la  VCS  soit  dans  un  groupe  sans  isolement  de  la  VCS.  Le  critère  principal  de  jugement
était basé  sur  les  récidives  de  FA  ou  d’autres  arythmies  atriales.
Résultats.  — Sur  une  période  de  18  mois,  100  patients  consécutifs  avec  FAP  (56  ±  9  ans  ;
17 femmes)  ont  été  inclus,  51  pts  dans  le  groupe  1  et  49  pts  dans  le  groupe  2.  Au  cours  d’un
suivi de  15  ±  8  mois  après  une  seule  procédure,  84  %  étaient  asymptomatiques  avec  absence  de
récidives,  alors  que  86  %  étaient  asymptomatiques  après  2  procédures.  Les  récidives  d’arythmies
étaient les  suivantes  :  1  tachycardie  atriale  (1  %),  8  FAP  (14  %),  1  FA  persistante  (1  %).  Le  suivi  à
long-terme  n’a  pas  montré  de  différence  signiﬁcative  entre  les  2  groupes,  avec  6/51  récidives
(12 %)  dans  le  VCS  +  VP  groupe  (FAP,  n  =  5  ;  TA,  n  =  1)  contre  9/49  patients  (18  %)  dans  le  VCS
groupe (FAP,  n  =  9  ;  p  =  0,6).  Deux  paralysies  phréniques  ont  été  observées  dans  le  groupe  1  avec
récupération  totale  dans  un  cas.
Conclusions.  —  Cette  étude  randomisée  avec  la  technique  du  robot  magnétique  montre  que
l’isolation systématique  de  la  VCS  en  combinaison  avec  l’isolement  des  VPs  ne  réduit  pas  le
risque d’arythmies  atriales  mais  au  contraire  expose  les  patients  à  d’autres  complications
comme la  paralysie  phrénique.
©  2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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or  several  years  now,  radiofrequency  ablation  (RFA)  ther-
py  has  played  a  decisive  role  in  the  treatment  of  complex
rrhythmias  and,  particularly,  atrial  ﬁbrillation  (AF)  [1—3].
o  date,  RFA  of  paroxysmal  atrial  ﬁbrillation  (PAF)  has
ocused  on  pulmonary  vein  isolation  (PVI),  regardless  of
hether  the  PVI  approach  was  segmental  or  circumferential
1,4,5].  However,  despite  initial  positive  results,  signiﬁ-
ant  recurrences  occurred  after  the  ﬁrst  procedure,  partly
d
i
a
tecause  of  pulmonary  vein  (PV)  reconnection,  although
on-PV  ectopic  foci,  including  the  superior  vena  cava
SVC),  might  also  be  implicated  [6—10].  Applying  a  strat-
gy  of  SVC  isolation  (SVCI)  in  addition  to  PVI  appears  to
mprove  the  outcome  of  AF  ablation  solely  in  patients
xhibiting  PAF  [11,12], although  this  is  still  subject  to
ebate.  There  are,  in  fact,  only  two  randomized  stud-
es  available,  which  are  hampered  by  several  limitations
nd  contradictory  results  [12,13].  We  therefore  need  fur-
her  investigation  into  whether  SVCI  combined  with  PVI
w
i
m
D
t
t
i
T
T
t
i
p
i
t
t
w
a
t
w
v
R
F
i
s
w
w
p
t
r
w
2
w
C
T
r
b
a
t
c
S
o
r
i
e
t
t
w
c
e
t
w
b
m
iSuperior  vena  cava  and  atrial  ﬁbrillation  ablation  
provides  additional  clinical  beneﬁts  in  a  PAF  population
[12,13].
The  only  beneﬁcial  randomized  study  available,  by
Corrado  et  al.,  involved  procedures  performed  with  non-
irrigated  catheters,  and  clinical  evaluation  seems  to  have
been  obtained  retrospectively  [12].  Conversely,  Wang  et  al.
did  not  ﬁnd  any  additional  beneﬁts,  but  their  study  follow-up
was  short  term,  and  patients  were  randomized  before  evalu-
ation  of  SVC  arrhythmogenicity  [13].  Moreover,  no  data  exist
concerning  the  feasibility  of  SVCI  using  the  remote  magnetic
navigation  system  (RMNS),  which  was  developed  with  the
aim  of  improving  the  beneﬁt-to-risk  ratio  for  both  patient
and  operator  [14—19].
This  study  had  two  objectives:  ﬁrst,  to  prospectively
compare  the  effect  of  PVI  plus  SVCI  versus  PVI  alone  on  PAF
patient  outcome;  second,  to  determine  SVCI  feasibility  using
the  RMNS.
Methods
Catheter  ablation  was  performed  remotely  via  the  Niobe®
II  RMNS  (Stereotaxis,  St.  Louis,  MO,  USA),  combined  with
a  new  three-dimensional  (3D)  non-ﬂuoroscopic  navigation
system  (CARTO® 3  System;  Biosense  Webster,  Diamond  Bar,
CA,  USA),  in  100  consecutive  patients  who  underwent  PV
disconnection  for  symptomatic  drug-refractory  paroxysmal
AF.  Randomization  was  only  carried  out  at  the  time  of  the
procedure  if  the  circular-mapping  catheter  placed  above
the  right  atrium  (RA)-SVC  junction  revealed  active  elec-
trical  potentials  in  the  SVC  (detected  in  sinus  rhythm  or
under  stimulation).  Patients  with  persistent  and  permanent
AF  were  excluded  from  participation,  as  were  those  with
an  electrically  silent  RA-SVC  junction.  All  patients  provided
written  informed  consent  before  the  procedure,  but  were
only  included  if  their  SVC  was  electrically  active,  with  all
patients  blinded  to  their  group  assignment.
Electrophysiological procedures
All  patients  received  anticoagulation  therapy  with  vitamin
K  antagonists  (VKA)  over  a  minimum  period  of  at  least
2  months  before  the  procedure  (target  international  nor-
malized  ratio,  2  to  3),  and  therapeutic  anticoagulation
was  maintained  with  intravenous  or  low-molecular-weight
heparin,  with  treatment  commencing  after  VKA  discontinu-
ation  and  3  days  before  the  intervention.  Transoesophageal
echocardiography  was  performed  within  the  48  hours  before
the  procedure,  to  exclude  left  atrial  (LA)  thrombus.  VKA
administration  was  resumed  on  the  day  after  the  procedure,
and  effective  anticoagulation  was  maintained  with  heparin
until  the  international  normalized  ratio  was  >  2.0.  Surface
electrocardiograms  and  bipolar  endocardial  electrograms
(ﬁltered  from  30  to  500  Hz)  were  monitored  continuously  and
recorded  on  a  computer-based  digital  ampliﬁer-recorder
system.  A  deﬂectable  quadripolar  catheter  (5  mm  interelec-
trode  spacing;  Xtrem;  ELA  Medical,  Montrouge,  France)  was
positioned  in  the  coronary  sinus  to  carry  out  pacing  and
recording.  The  left  atrium  (LA)  was  accessed  either  via
a  patent  foramen  ovale,  when  present,  or  by  transseptal
puncture.  A  guidewire  was  inserted  into  the  LA  using  an
8F  sheath.  Over  the  course  of  the  procedure,  the  sheath
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as  perfused  with  heparinized  solution  (3000  U  of  heparin
n  500  mL  of  sodium  chloride  0.9%  at  a  rate  of  150  mL/h).  A
ultipolar  deﬂectable  catheter  (LASSO®;  Biosense  Webster,
iamond  Bar,  CA,  USA)  was  inserted  through  the  long  sheath
o  enable  the  mapping  of  the  PV  ostia  required  for  the  abla-
ion  procedures.  RFA  was  performed  using  a  3.5  mm  open
rrigated-tip  magnetic  ablation  catheter  (NAVISTAR® RMT
hermoCool®; Biosense  Webster,  Diamond  Bar,  CA,  USA).
he  catheter  was  introduced  into  the  LA  through  a second
ransseptal  puncture;  the  venous  sheath  was  then  withdrawn
nto  the  RA  and  continuously  perfused.  After  the  transseptal
uncture,  intravenous  unfractionated  heparin  was  admin-
stered  as  a bolus  (7500  U);  additional  boluses  were  given
hroughout  the  procedure  to  ensure  an  activated  clotting
ime  of  at  least  300  seconds.  The  activated  clotting  time
as  determined  30  minutes  after  the  transseptal  puncture
nd  every  30  minutes  thereafter.  When  the  activated  clot-
ing  time  was  <  300  seconds,  an  additional  bolus  of  2500  U
as  administered.  Deep  sedation  was  achieved  using  intra-
enous  nalbuphine  and  midalzolam.
adiofrequency catheter ablation procedures
or  both  study  groups,  the  endpoint  of  ablation  was  the
solation  of  the  PVs,  deﬁned  by  complete  elimination  or  dis-
ociation  of  pulmonary  potentials,  conﬁrmed  in  all  cases
ith  a  circumferential  mapping  catheter.  Radiofrequency
as  applied  using  an  open  irrigated-tip  catheter,  with  a
ower  output  not  exceeding  35  W  when  positioned  close  to
he  PV  ostia,  and  not  exceeding  25  W  when  in  the  poste-
ior  part  of  the  PV  ostia  or  the  SVC  ostia.  Tip  irrigation
as  achieved  by  using  sodium  chloride  0.9%  at  a  rate  of
0—35  mL/min  to  maintain  a tip  temperature  of  <  43 ◦C.  SVCI
as  performed  by  segmental  ablation  in  all  cases.
ARTO® 3 System features
his  study  used  the  CARTO® 3 System,  which  allows  for
eal-time  advanced  catheter  location  and  visualization  of
oth  ablation  and  circular-mapping  catheters  (NAVISTAR
nd  LASSO).  The  catheter  location  display  was  identical
o  that  of  the  ﬂuoroscopic  view.  The  CARTO® 3  System
ombines  electromagnetic  technology  (as  in  the  CARTO  XP
ystem)  with  new  Advanced  Catheter  LocationTM technol-
gy  that  enables  visualization  of  multiple  catheters  without
equiring  ﬂuoroscopy.  Brieﬂy,  Advanced  Catheter  Location
s  an  impedance-based  catheter  localization  system  that
nables  precise  cardiac  mapping  and  navigation  with  mul-
iple  electrodes.  Six  electrode  patches  were  attached  to
he  body  surface,  constantly  monitoring  the  current,  which
as  emitted  at  a  frequency  unique  to  each  individual
atheter  electrode.  In  addition,  each  electrode  patch  was
quipped  with  a  magnetic  sensor,  enabling  3D  localiza-
ion.  The  currents  detected  at  the  patches  were  associated
ith  the  3D  positioning  of  the  electrode  inside  the  human
ody.  The  ability  of  the  CARTO® 3 System  to  visualize  the
anipulation  and  placement  of  circular-mapping  catheters
n  each  vein  could  further  reduce  the  duration  of  ﬂuo-
oscopy  procedures.  This  system  also  improved  catheter
tability  during  ablation  and  facilitated  the  identiﬁcation  of
ach  catheter  electrode  pair  position.  The  visualization  of
atheters  and  electrode  pairs  was  provided  via  a  real-time
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n-screen  display  of  a  geometrically-reliable  icon  represent-
ng  the  distal  part  of  the  LASSO  catheter  along  with  the
lectrode  positions.  LA  reconstruction  was  obtained  using
 fast  anatomical  map  algorithm.  This  method  produced
 continuous  (non-gated)  record  of  the  movements  of  the
agnetic  NAVISTAR  catheter.  Based  on  this  volume  sampling,
urface  reconstruction  was  built  in  accordance  with  the  set
esolution  level.  On  completion  of  the  map,  a  3D  computed
omography  scan  was  performed  to  optimize  LA  reconstruc-
ion.
emote magnetic navigation system
he  Niobe  II  RMNS  is  a  technological  platform  that  employs  a
teerable  magnetic  ﬁeld  to  remotely  guide  a  supple  catheter
nside  the  heart  [14—19].  The  steerable  magnetic  ﬁeld  con-
ains  two  giant  computer-controlled  1.8  tonne  magnets
ositioned  on  opposite  sides  of  the  ﬂuoroscopy  table.  A
agnetic  ﬁeld  of  0.08  to  0.1  Tesla  was  generated  (accord-
ng  to  the  initial  choice)  so  that  the  three  small  magnets
ncorporated  in  parallel  into  the  tip  of  the  radiofrequency
atheter  could  enable  3D  navigation.  The  magnetic  ﬁeld  was
pplied  to  a  theoretical  cardiac  volume  of  20  cm  ×  20  cm.
y  means  of  a  vector-based  computer  system  (Navigant  2.1;
tereotaxis  Inc.,  St.  Louis,  MO,  USA),  precision  guiding  of  the
atheter  tip  was  possible.  This  system  operated  by  aligning
he  catheter  to  the  generated  magnetic  ﬁeld,  making  the
ovements  of  the  catheter  dependent  on  the  changes  in
irection  of  the  two  magnets,  each  in  relation  to  the  other.
 computerized  motor  drive  system  (Cardiodrive®; Stereo-
axis  Inc.,  St.  Louis,  MO,  USA)  advanced  or  retracted  the
atheters,  whereas  the  computerized  work  station  (Navigant
.1)  was  required  to  guide  their  orientation  in  space.  Using
 keypad  (arrows)  or  joystick,  the  catheter  could  be  con-
inuously  advanced,  retracted  or  even  adjusted  (from  1  mm
o  9  mm).  Use  of  the  second-generation  Niobe  II  enabled  us
o  tilt  the  magnets  at  angles  ranging  from  40◦ left  ante-
ior  oblique  to  30◦ right  anterior  oblique.  The  magnetic
eld  was  constantly  generated  during  the  ablation  proce-
ure,  thus  keeping  the  catheter  tip  in  permanent  contact
ith  the  endocardial  tissue  throughout  the  cardiac  cycle,
nd  therefore  improving  the  delivery  of  the  radiofrequency
urrents.  Given  that  the  magnetic  ﬁeld  exerted  a  weak  force
15—20  gm)  and  the  catheter  was  very  ﬂexible,  navigation
nside  the  heart  was  highly  reliable,  with  nearly  zero  risk  of
erforation  [14—19].  The  system  was  able  to  store  certain
ata,  such  as  the  position  of  veins,  and  these  vectors  could
hen  be  reapplied  during  examination  to  facilitate  catheter
avigation  or  reduce  procedure  time.
easurements: procedural and ﬂuoroscopy
ariables
he  following  variables  were  recorded  for  all  patients  and
ere  compared  between  study  groups:  total  duration  time
skin  to  skin);  total  X-ray  procedure  time,  from  needle
nsertion  to  ultimate  catheter  removal;  skin  to  catheter
ositioning  X-ray  time,  from  femoral  access  to  the  ﬁnal
atheter  positioning  in  the  LA,  including  transseptal  access;
A  electroanatomical  mapping  X-ray  time,  from  catheter
ositioning  in  the  LA  to  satisfactory  electroanatomical
econstruction  compared  with  LA  computed  tomography
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can;  ablation  X-ray  time  from  ﬁrst  to  last  radiofrequency
elivery.
ndpoints
he  procedure  endpoint  was  PVI,  conﬁrmed  in  all  patients
y  spiral  catheter  recording  during  ablation.  PVI  was  deﬁned
s  abolition  or  dissociation  of  activities  in  all  PVs.  PV  poten-
ials  and  far-ﬁeld  potentials  were  distinguished  by  means  of
 pacing  technique  from  the  LA,  LA  appendage  or  coronary
inus,  using  the  ablation  or  quadripolar  catheter.  Segmen-
al  ablation  was  deﬁned  as  targeting  the  earliest  RA-SVC
onduction  in  cases  where  the  RA-SVC  conduction  sequence
ould  be  detected  in  the  sinus  rhythm  or  by  RA  or  proxi-
al  coronary  sinus  pacing.  SVCI  was  characterized  as  the
isappearance  of  SVC  potentials  or  dissociation  of  SVC
otentials  with  RA  activity.  Phrenic  nerve  injury  preven-
ion  was  achieved  by  avoiding  the  posterolateral  wall  or  by
igh-output  pacing  stimulation  (30  mA).  Procedural  data  was
ollected,  including  X-ray  exposure  and  complications.
ollow-up
atients  were  hospitalized  for  3  days  post-procedure,  as
tandard,  with  a  2-month  blanking  period.  The  blanking
eriod  was  deﬁned  as  the  interval  during  which  early
ecurrences  were  considered  a transient  phenomenon  rather
han  a  procedure  failure.  Antiarrhythmic  medication  was
ontinued  for  at  least  3  months  and  then  stopped.  VKA
dministration  was  continued,  taking  into  account  the
HA2DS2-VASc  score.  Success  was  deﬁned  as  the  absence
f  any  documented  arrhythmia  or  symptoms  suggestive
f  arrhythmia  recurrences  (atrial  tachycardia  [AT],  atrial
utter  and  AF).  We  performed  24-hour  Holter  monitoring
ach  time  a  patient  experienced  palpitations.  Patients  were
ollowed-up  clinically  every  6  months,  and  a  redo  procedure
as  permitted  > 6  months  after  the  index  procedure,  at  the
equest  of  the  patient.  We  systematically  performed  24-
our  Holter  monitoring  at  the  end  of  follow-up,  and  assessed
ong-term  complications.  The  patient  and  the  medical  prac-
itioner  who  carried  out  the  follow-up  were  blinded  to  the
atient’s  group  assignment.
tatistical analysis
he  baseline  characteristics  of  the  patients  were  exam-
ned  using  Fisher’s  exact  test  for  categorical  variables  or
 t-test.  The  differences  between  groups  were  analysed
y  analysis  of  variance.  Summary  values  are  expressed  as
eans  ±  standard  deviations.  All  reported  levels  of  signiﬁ-
ance  were  two-sided.  A probability  value  of  P  <  0.05  was
onsidered  statistically  signiﬁcant.  We  estimated  that  the
nrolment  of  100  patients  with  symptomatic  paroxysmal
F  would  be  necessary  to  detect  a  20%  reduction  in  AF
ecurrence  in  the  PVI  plus  SVCI  group  versus  in  the  PVI
lone  group,  with  80%  power  and  a  two-sided    level  of
.05.  The  primary  endpoint  was  time  to  symptomatic  AF
ecurrence,  conﬁrmed  by  electrocardiogram  or  Holter  moni-
oring.  The  secondary  endpoint  was  symptom  evaluation  and
ccurrence  of  other  atrial  arrhythmias.  The  primary  analysis
as  an  intention-to-treat  comparison  of  time  to  AF  recur-
ence.  For  all  time-to-event  analyses,  rates  were  estimated
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Table  1  Patient  characteristics  (n  =  100).
Age  (years)  56  ±  9
Women  17
Arterial  hypertension  32
Diabetes  mellitus 4
Tobacco  use 2
Hypercholesterolaemia  18
CHA2DS2-VASc  score 0.9  ±  1
Duration  of  atrial  ﬁbrillationa (months)  49  ±  37
Structural  heart  disease  18
History  of  atrial  ﬂutter  34
Left  ventricular  ejection  fraction  (%)  63  ±  7
Transversal  left  atrial  diameter  (mm) 42  ±  2
Left  atrial  surface  (cm2)  19  ±  5
Number  of  antiarrhythmic  agents  testeda 2  ±  1
CHA2DS2-VASc: cardiac failure or dysfunction, hypertension,
age ≥ 75 (doubled), diabetes, stroke (doubled)-vascular disease,
age 65—74 and sex category (female).
Data are mean ± standard deviation or %, unless otherwise
stated.
a
Figure 1. Kaplan-Meier estimates of the percentage of patients
remaining free of recurrence of atrial arrhythmias in the pul-
monary vein isolation (PVI) + superior vena cava isolation (SVCI)
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by  means  of  the  Kaplan-Meier  method  and  were  compared
using  the  log-rank  test.  Patient  data  were  censored  at  time
of  last  contact,  withdrawal  from  the  study  or  death.  Symp-
tomatic  and  asymptomatic  episodes  of  AF  were  recorded.
The  authors  had  full  access  to  the  data  and  assume  complete
responsibility  for  its  integrity.  All  authors  have  read  and
agreed  to  the  manuscript  as  written.  All  analyses  were  per-
formed  using  StatView® 5.0  (StatView  IV;  Abacus  Concept,
Berkeley,  CA,  USA).
Results
Baseline population characteristics
Baseline  clinical  data  are  summarized  in  Table  1.  In  total,
100  patients  were  prospectively  included,  with  the  follow-
ing  patient  characteristics:  mean  age  was  56  ±  9  years;  17%
were  female;  mean  LA  diameter  was  41  ±  7  mm;  18%  pre-
sented  with  structural  heart  disease.  The  percentage  of
complete  circumferential  isolation,  as  conﬁrmed  by  spiral
catheter  recording  during  ablation,  was  97%  for  the  PVs
and  100%  for  the  SVC.  No  signiﬁcant  difference  in  variables
was  revealed  on  comparison  of  SVCI  plus  PVI  with  PVI  alone
(Table  2).
Total ﬂuoroscopy (median ± interquartile)
The  median  duration  of  the  procedure  (±  interquartile)
was  2.5  ±  1  hours;  total  X-ray  exposure  time  was
13.3  ±  8  minutes;  transseptal  puncture  and  catheter
g
g
troup (orange line) versus PVI alone (blue line). AF: atrial ﬁbril-
ation.
ositioning  time  was  8  ±  5  minutes;  LA  electroanatomi-
al  reconstruction  time  was  3  ±  2  minutes;  and  catheter
blation  time  was  3.7  ±  3  minutes.
linical outcome
fter  a  median  follow-up  of  15  ±  8  months,  and  hav-
ng  undergone  a  single  procedure,  84%  of  patients  were
ymptom  free,  while  86%  remained  asymptomatic  after
ndergoing  two  procedures.  We  observed  the  following
ecurrences:  AT  in  one  (1%)  patient,  paroxysmal  AF  in  eight
14%)  patients  and  persistent  AF  in  one  (1%)  patient.  Redo
blation  was  performed  in  six  (6%)  patients,  because  of  AT  in
ne  (1%)  patient  and  paroxysmal  AF  in  ﬁve  (5%)  patients.  The
umulative  risks  of  atrial  arrhythmias,  such  as  AT  or  AF,  were
ssessed  using  Kaplan-Meier  curves  and  compared  using
he  log-rank  test.  Long-term  follow-up  revealed  no  signiﬁ-
ant  difference  between  the  groups,  with  atrial  arrhythmias
ccurring  in  six  (12%)  of  51  patients  in  the  PVI  +  SVCI  group
AF,  n  =  5;  AT,  n  =  1)  and  nine  (18%)  of  49  patients  in  the  PVI
lone  group  (AF,  n  =  9;  P  =  0.6)  (Fig.  1).  No  tamponade  was
oted,  and  no  char  formation  was  found  on  the  catheter  tip
pon  its  removal.
Functional  status  was  assessed,  and  we  found  no  signiﬁ-
ant  difference  between  the  PVI  +  SVCI  and  PVI  alone  groups,
s  shown  by  these  respective  ﬁgures:  44  of  51  (86%)  vs.  39  of
9  (80%)  asymptomatic;  and  7  of  51  (14%)  vs.  10  of  49  (20%)
P  =  0.2)  partially  ameliorated  or  not  ameliorated.
omplications
o  sinus  node  injury  or  tamponade  was  observed  in  our
eries  of  ablation  procedures.  Four  serious  complications
ccurred:  one  severe  symptomatic  pulmonary  stenosis
equiring  stenting  in  the  PVI  alone  group;  one  transient
schaemic  attack  with  complete  recovery  in  the  PVI  alone
roup;  one  transient  phrenic  nerve  palsy  in  the  PVI  +  SVCI
roup;  and  one  phrenic  nerve  injury  with  partial  recovery  in
he  PVI  +  SVCI  group.
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Table  2  Comparison  of  superior  vena  cava  isolation  plus  pulmonary  vein  isolation  and  pulmonary  vein  isolation  alone.
Characteristic  PVI  +  SVCI(n =  51)  PVI  alone(n =  49)  P
Age  (years)  55  ±  10  58  ±  9  0.3
Female  11  (21.6)  10  (20.4)  0.5
Structural  heart  disease  8  (15.7)  33  (67.3)  0.7
Hypertension  16  (31.3)  16  (32.7)  0.9
Diabetes  mellitus  1  (2.0)  3  (6.1)  0.3
Cholesterol  10  (19.6)  8  (16.3)  0.7
Tobacco  use 11 (21.6) 11  (22.4) 0.9
Duration  of  atrial  ﬁbrillationa (months) 47.5  ±  30 50  ±  44 0.7
CHA2DS2-VASc  score  0.8  ±  0.9  1  ±  1  0.5
Left  atrial  systolic  diameter  (mm)  42  ±  7  39  ±  6  0.3
Left  ventricular  ejection  fraction  (%)  63  ±  7  64  ±  7  0.6
Procedure  duration  (hours)  2.4  ±  0.6  2.5  ±  0.8  0.6
Total  X-ray  exposure  time  (minutes)  14  ±  5  15  ±  6  0.4
X-ray  time  dedicated  to  radiofrequency  (minutes)  3.6  ±  2.7  3.8  ±  3.3  0.7
Long-term  follow-up
Atrial  arrhythmias  6  (11.8)  9  (18.4)  0.6
Atrial  ﬁbrillation 5  (9.8)  9  (18.4)
Atrial  tachycardia  1  (2.0)  —
PVI: pulmonary vein isolation; SVCI: superior vena cava isolation; CHA2DS2-VASc: cardiac failure or dysfunction, hypertension, age ≥ 75
(doubled), diabetes, stroke (doubled)-vascular disease, age 65—74 and sex category (female).
Data are mean ± standard deviation or number (%), unless otherwise stated.
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iscussion
ajor ﬁndings
his  randomized,  single-centre,  prospective  study  has
stablished  that  a  strategy  combining  SVCI  with  PVI  yields
imilar  long-term  clinical  results  to  PVI  alone  in  symptomatic
AF  patients;  this  approach  must  not,  therefore,  be  used
s  standard  in  clinical  practice.  Moreover,  although  the  risk
f  phrenic  nerve  damage  is  low,  this  side-effect  could  be
xtremely  detrimental,  particularly  in  a  young  population.
he  study  has  also  established  that  segmental  RFA  isolation
ia  RMNS  is  feasible,  without  causing  additional  risk,  and
hat  the  procedure  is  not  time  consuming.  Accordingly,  RMNS
epresents  the  optimal  tool  for  performing  effective  AF  abla-
ion,  with  the  ultimate  aim  of  reducing  patient  and  operator
-ray  exposure  and  limiting  operator  fatigue.  Finally,  the  use
f  a  ﬂexible  magnetic  catheter  considerably  increases  the
afety  of  complex  procedures  like  AF  RFA.
uperior vena cava and atrial ﬁbrillation
everal  studies  have  clearly  established  PVs  as  the  principal
rigin  of  ectopies  that  initiate  PAF  [1,20],  despite  the
ccurrence  of  PVI  recurrences,  caused  by  PV  reconnection
r  ectopies  originating  from  other  sources,  such  as  the
oronary  sinus  or  the  ligament  of  Marshall  [8].  Ectopies
b
L
2
triginating  in  the  SVC  or  RA  can  also  provoke  AF,  as  reported
n  several  publications  [6,8,10,20—22].  SVC  arrhythmo-
enicity  could  be  caused  by  anatomical  muscle  input  from
he  RA  provoking  anisotropy  because  of  cardiomyocyte  size
nd  assembly  [8,23]. Anatomical  studies  have  reported  that
he  RA-SVC  junction  is  formed  by  discontinued  myocardial
leeves  protruding  by  13  mm  (mean  thickness  1.2  mm)  into
he  SVC,  as  has  been  observed  in  PV  sleeves  [24].  A  recent
tudy  focusing  on  SVC  arrhythmogenicity  factors  suggested
hat  a  long  SVC  sleeve  (>  30  mm)  and  a  large  SVC  potential
>  1  mV)  strongly  predict  SVC  AF  foci  [25]. Working  on  the
asis  of  these  conclusions,  several  authors  have  investigated
he  role  of  SVC  arrhythmogenicity  in  the  clinical  setting
6,9,22]. For  example,  Goya  et  al.  assessed  16  PAF  patients
fter  PVI,  and  discovered  a  sharp  potential  existing  inside
he  SVC,  with  a  similar  breakthrough  to  that  in  the  PV  [6].
VC  potentials  were  detected  over  a  large  circumference,
uggesting  widespread  muscle  coverage  of  the  SVC  [6].
he  same  authors  also  proved  the  feasibility  of  SVCI  [6].  In
 series  of  293  patients  with  clinically  documented  drug-
efractory  PAF,  Lee  et  al.  sought  to  determine  predictors  of
on-PV  ectopic  beats  initiating  PAF  [22].  Of  94  patients  with
on-PV  ectopic  beats  initiating  PAF,  38  (40%)  had  SVC  ectopic
eats,  representing  13%  of  the  overall  PAF  population  [22].
in  et  al.  reported  similar  results  with  SVC-originated  PAF  in
7  (37%)  of  68  cases  with  non-PV-originated  AF  [9],  although
his  prevalence  was  difﬁcult  to  substantiate,  as  other
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studies  had  reported  prevalence  rates  ranging  from  3.7%  to
12%  [11,13].  Given  the  unknown  role  of  SVC  in  AF  genesis
or  perpetuation,  such  as  that  observed  in  clinical  practice
with  PVs,  systematic  SVCI  from  the  RA  could,  therefore,
impact  PAF  RFA  results,  as  has  been  reported  [11,12].
Superior vena cava isolation and clinical
studies
The  debate  surrounding  the  need  to  perform  SVCI  routinely
in  every  AF  patient  has  yet  to  be  resolved  [26].  Despite
the  efﬁcacy  of  PVI,  and  in  order  to  improve  success  rates
and  reduce  recurrence  rates,  some  authors  have  investi-
gated  the  clinical  role  of  SVCI  [8,9,11—13,26].  Lin  et  al.
showed  that  20%  of  recurrences  were  initiated  by  SVC  trigg-
ers,  especially  the  late  recurrences  (>  12  months)  [8].  In
order  to  increase  AF  RFA  success  rates,  targeting  SVC  RA
triggers  could  be  a  reasonable  adjunctive  strategy,  as  SVCI
appears  both  feasible  and  safe,  especially  if  the  procedure
is  guided  by  a  3D  non-contact  or  contact  system  and  includes
a  detailed  geometry  of  the  SVC,  sinus  node  location  and
phrenic  nerve  route  [6,11,26].  Thus,  Arruda  et  al.  assessed
the  feasibility  of  empirical  SVC  electrical  isolation  combined
with  PVI  in  symptomatic  AF  patients  [11],  performing  the
procedure  in  208  out  of  217  patients  exhibiting  SVC  poten-
tials,  with  SVCI  obtained  in  only  127  (59%)  patients  [11].
This  study  was  limited  by  the  lack  of  randomization,  and
by  the  authors  only  conﬁrming  the  feasibility  and  clinical
efﬁcacy  of  SVCI  in  the  subset  of  patients  showing  SVC  trigg-
ers  initiating  AF  during  the  procedure  (n  =  24),  who  were
symptom  free  at  long-term  follow-up  [11].  Because  of  the
various  limitations  of  the  published  studies,  SVCI  needed
further  investigation  [11,26].  There  are  only  two  random-
ized  studies  available;  each  had  several  limitations  and  they
produced  contradictory  results  [12,13].  Corrado  et  al.  were
the  only  investigators  to  report  beneﬁcial  results  in  a ran-
domized  study  of  empirical  electrical  SVC  plus  PV  isolation,
but  some  limitations  may  have  inﬂuenced  their  study  results
[12]:  the  RFA  procedures  were  performed  with  non-irrigated
catheters  (an  8  mm  tip  catheter);  and  the  only  positive  result
was  obtained  in  the  PAF  group,  which  was  an  analysis  sub-
group  [12].  Using  an  8  mm  tip  allowed  SVCI  in  84%  of  cases,
and  in  the  overall  population-based  intention-to-treat  anal-
ysis,  no  difference  was  revealed  between  SVCI  plus  PVI  (81%)
versus  PVI  alone  (74%)  after  12  months  (P  =  0.16)  [12].  Con-
versely,  Wang  et  al.  did  not  ﬁnd  any  additional  beneﬁts,  but
their  study  follow-up  was  short  term,  and  patients  were  ran-
domized  before  evaluation  of  SVC  arrhythmogenicity;  both
of  these  limitations  could  have  affected  the  results  [13].
Our  study  used  a  prospective,  randomized  design,  and  both
patients  and  medical  practitioners  carrying  out  the  follow-
up  were  blinded  to  patient  group  assignment.  Our  study
results  revealed  no  additional  clinical  effects  of  SVCI  on
long-term  follow-up  (15  months).  Moreover,  the  presence  of
SVC  connection  and  the  absence  of  RFA  impact  on  AF  recur-
rence  do  not  support  the  role  of  RA  arrhythmogenicity  in
patients  with  paroxysmal  symptomatic  AF.  In  combination
with  the  literature  analysis,  our  results  therefore  conﬁrmed
that  SVCI  may  be  useful  in  only  a  subset  of  AF  patients  with
demonstrated  SVC  triggers  initiating  AF.  Empirical  electrical
c
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solation  combined  with  pulmonary  isolation  does  not  appear
o  be  required  in  a  symptomatic  PAF  population.
otential complications related to superior
ena cava isolation [27—29]
ith  SVCI,  there  is  the  potential  for  transient  or  permanent
iaphragmatic  paralysis  as  a  result  of  phrenic  nerve  ther-
al  injury.  Two  patients  (2%)  in  our  population  exhibited  a
hrenic  palsy:  transient  in  one  case;  and  with  partial  recov-
ry  in  the  other.  This  lesion  can  be  avoided  by  pacing  at
he  posterolateral  part  of  the  SVC  with  high-output  (30  mA)
29]. Sinus  node  injury  can  occur  if  the  ablation  sites  are
ocated  closer  to  the  sinus  node.  This  complication  did  not
rise  in  our  study,  probably  because  of  our  use  of  segmental
solation,  the  3D  geometry  of  the  atrium  and  SVC  with  the
ARTO® 3  System,  and  RMNS  facilitating  very  stable  catheter
ositioning.  Lastly,  SVC  stenosis  could  occur,  although  pre-
ention  is  possible  through  a signal  segmental  approach  and
D  CARTO  geometry,  in  order  to  stay  in  close  proximity  to  the
VC  ostium  [11—13,26]. If  necessary,  therefore,  SVCI  should
e  performed  below  the  level  of  both  the  SVC  triggers  and
he  phrenic  nerve  capture  site,  and  above  the  level  of  the
inus  node  origin  [27—29].
linical implications
his  randomized,  prospective  study  sought  to  investigate  the
ole  of  SVC  arrhythmogenicity  on  subsequent  atrial  arrhyth-
ia  risk  after  PVI.  Our  study  established  that  empirical  SVCI
ffered  no  beneﬁts  to  patients  with  symptomatic  paroxys-
al  AF.  To  the  best  of  our  knowledge,  no  study  has  yet  tested
he  feasibility,  safety  and  efﬁcacy  of  RMNS  when  attempting
o  isolate  the  SVC.  Furthermore,  the  vicinity  of  structures
uch  as  the  phrenic  nerve  and  the  sinus  node  could  rep-
esent  a  potential  risk  with  SVC  ablation.  The  occurrence
f  two  phrenic  nerve  injuries  in  the  SVCI  group,  together
ith  the  non-signiﬁcant  reduction  in  subsequent  AF  recur-
ence,  argue  against  systematic  SVCI  because  of  the  poor
eneﬁt-to-risk  ratio.  SVCI  should  therefore  be  reserved  for
atients  presenting  with  recurrent  AF,  with  no  PV  recov-
ry  conduction,  and  exhibiting  SVC  triggers  initiating  AF
pisodes.
tudy limitations
he  major  limitations  of  this  study  were  its  single-centre
tudy  design  and  its  small  sample  size.  However,  it  should
e  noted  that  we  were  able  to  provide  longer-term  follow-
p  results  than  those  published  so  far.  Furthermore,  this
tudy  only  involved  patients  with  electrical  SVC  connection.
evertheless,  multicentre,  randomized  studies  are  difﬁcult
o  perform,  particularly  when  using  the  same  technology
RMNS)  throughout.  Although  our  follow-up  does  not  pre-
lude  that  asymptomatic  AF  occurred,  it  is  of  note  that  we
nrolled  only  symptomatic  PAF  patients,  and  in  this  context,
reedom  from  symptoms  appears  to  be  a  clinically  relevant
riterion.
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onclusions
his  randomized  study  has  established  that  SVCI  in  com-
ination  with  PVI  does  not  reduce  the  risk  of  subsequent
F  recurrence,  and  was  responsible  for  two  phrenic  nerve
njuries.  Accordingly,  systematic  SVCI  does  not  appear  to  be
equired  routinely  in  AF  ablation,  given  the  poor  beneﬁt-to-
isk  ratio.
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